• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 8, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Tongue microbiome could help identify patients with early-stage pancreatic cancer

Bioengineer by Bioengineer
January 29, 2019
in Cancer
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Oleg Magni from Pexels


Differences in the abundance of certain bacteria living on the tongue can distinguish patients with early pancreatic cancers from healthy individuals, according to results from a new study published in the Journal of Oral Microbiology.

Although disruptions to the microbiome – the population of microorganisms that live in and on our bodies – have already been identified in pancreatic cancer patients in other body tissues, this is the first evidence of changes to the bacteria in the tongue coating. If confirmed in larger studies, this could pave the way towards the development of new life-saving early detection or prevention tools for this highly aggressive disease.

Nearly 10,000 people are diagnosed with pancreatic cancer in the UK each year, with less than one per cent surviving beyond ten years. An early diagnosis can greatly improve the chances of successful treatment – but this poses challenges for this disease as it grows deep inside the body and often shows few symptoms before it has already spread. As a result, most patients already have advanced disease by the time they seek medical help.

Researchers are searching for biological changes that can accurately detect early signs of pancreatic cancer, which could be developed into new screening tests. A current hot topic is the potential role of the microbiome in the development of cancer, with previous studies identifying dramatic disruptions to bacteria in saliva, intestinal and faecal samples collected from pancreatic cancer patients compared to healthy individuals.

In the first study to characterise the tongue coat microbiome of patients with pancreatic cancer, a team of researchers recruited a group of 30 patients with early-stage disease (diagnosed with a tumour positioned in the ‘head’ area of the pancreas) and a similar group of 25 healthy people. Participants were all between 45 and 65 years in age, had no other diseases or oral health problems and had not taken any antibiotics or other drugs for the three months before the study.

The team used sophisticated gene sequencing technologies to examine the microbiome diversity of tongue coat samples, finding that pancreatic cancer patients were colonised by remarkably different tongue coating microbiomes compared to healthy individuals.

Lead author Lanjuan Li of Zhenjiang University, China, said: “Although further confirmatory studies are needed, our results add to the growing evidence of an association between disruptions to the microbiome and pancreatic cancer.”

Strikingly, the abundance of four types of bacteria – low levels of Haemophilus and Porphyromonas and high levels of Leptotrichia and Fusobacterium – could distinguish pancreatic cancer patients from healthy individuals.

“If an association between the discriminatory bacteria and pancreatic cancer is confirmed in larger studies, this could potentially lead to the development of new microbiome-based early diagnostic or preventive tools for the disease,” said Li.

The research team hypothesize that the immune system is the most likely link between any confirmed shifts in the microbiome with pancreatic cancer – for example, disease development in the pancreas may influence the immune response in ways that favour the growth of certain bacteria – or vice versa. If proven, this could set the stage for the development of new treatment strategies involving antibiotics or immunotherapies – or potentially even probiotics that can help prevent pancreatic cancer in high-risk patients in the future.

###

FURTHER INFORMATION

To arrange an interview, please contact:

Ingar Olsen

Email: [email protected]

For a copy of the study, please contact:

Jodie Bell, Press & Media Relations Manager

Email: [email protected]

Tel.: +44 (0)20 7017 6571

Follow us on Twitter: @tandfnewsroom

The article will be freely available once the embargo has lifted via the following link: https://tandfonline.com/doi/full/10.1080/20002297.2018.1563409

About Taylor & Francis Group

Taylor & Francis Group partners with researchers, scholarly societies, universities and libraries worldwide to bring knowledge to life. As one of the world’s leading publishers of scholarly journals, books, ebooks and reference works our content spans all areas of Humanities, Social Sciences, Behavioural Sciences, Science, Technology and Medicine.

From our network of offices in Oxford, New York, Philadelphia, Boca Raton, Boston, Melbourne, Singapore, Beijing, Tokyo, Stockholm, New Delhi and Cape Town, Taylor & Francis staff provide local expertise and support to our editors, societies and authors and tailored, efficient customer service to our library colleagues.

Media Contact
Jodie bell
[email protected]
44-207-017-6571

Related Journal Article

http://dx.doi.org/10.1080/20002297.2018.1563409

Tags: cancerMedicine/HealthMicrobiology
Share20Tweet8Share2ShareShareShare2

Related Posts

Promising Outcomes from First-in-Human Trial of DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer

September 7, 2025

Phase 2 IDeate-Lung01 Trial Shows Ifinatamab Deruxtecan Achieves High Response Rates in Previously Treated Extensive-Stage Small Cell Lung Cancer

September 7, 2025

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

September 7, 2025

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

September 7, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Leaf Beetle Evolution Boosts Defense Against Shared Wasp

Evaluating Impact of Environment on Kenyan Donkey Welfare

Protecting Youth from the Risks of Sports Betting Advertising in Canada

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.